ArticleFrontiers in pharmacology2019
Breaking Glucose Transporter 1/Pyruvate Kinase M2 Glycolytic Loop Is Required for Cantharidin Inhibition of Metastasis in Highly Metastatic Breast Cancer.
Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Bibliometric Analysis and Systemic Review of Cantharidin Research Worldwide.Current pharmaceutical biotechnology · 2024Pooled it
- Natural products targeting glycolysis in cancer.Frontiers in pharmacology · 2022Pooled it
- Crocin I delays cellular senescence potentially via modulating SIRT1/PKM2 expression to improve lactate homeostasisExperimental and therapeutic medicine · 2026Article
- The GAP43/RAC1 axis drives glycolytic reprogramming and progression in lung adenocarcinoma.Respiratory research · 2026Article
- Targeting Lung Cancer Metabolism: Therapeutic Opportunities and Challenges.Advances in experimental medicine and biology · 2026Review
- Natural Medicines Modulating Tumor Perineural Invasion: Regulatory Mechanisms and Therapeutic Potential.Drug design, development and therapy · 2026Review
- An overview of the research progress on Mylabris: entomology, active ingredients, traditional use, pharmacology, clinical application, pharmacokinetics, toxicity and detoxification strategies.Chinese medicine · 2025Review
- P16-positive senescent cells promote DKD by the dysregulation of glycolysis and mitochondrial metabolism.Cell death discovery · 2025Article
- Research progress on the signaling pathway mechanism of terpenoids against breast cancer.Discover oncology · 2025Review
- Cantharidin: a double-edged sword in medicine and toxicology.Frontiers in pharmacology · 2025Review
- Mylabris: a review of its biological characteristics, chemical composition, pharmacological, toxicology, pharmacokinetics, and marketed drugs.Frontiers in pharmacology · 2025Review
- Mannich Base Derived from Lawsone Inhibits PKM2 and Induces Neoplastic Cell Death.Biomedicines · 2024Article
- Glycyrrhetinic acid-modified redox-sensitive polymeric mixed micelles for tumor-specific intracellular delivery of cantharidin.RSC advances · 2024Article
- Non-metabolic enzyme function of pyruvate kinase M2 in breast cancer.Frontiers in oncology · 2024Review
- GLUT-1/PKM2 loop dysregulation in patients with non-ST-segment elevation myocardial infarction promotes metainflammation.Cardiovascular research · 2023Article
- Cantharidin and Its Analogue Norcantharidin Inhibit Metastasis-Inducing Genes S100A4 and MACC1.International journal of molecular sciences · 2023Article
- Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma.Molecules (Basel, Switzerland) · 2022Article
- Bioactive constituents of animal-derived traditional Chinese medicinal materials for breast cancer: opportunities and challenges.Journal of Zhejiang University. Science. B · 2022Review
- Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway.Bioengineered · 2022Article
- Targeting glycolysis in non-small cell lung cancer: Promises and challenges.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aerobic glycolysis plays a decisive role in cancer growth. However, its role in cancer metastasis was rarely understood. Cantharidin a natural compound from an arthropod insect cantharis exerts potent anticancer activity. Here we found cantharidin possesses significant anti-metastatic activity on breast cancer dependent on inhibition of aerobic glycolysis. Cantharidin indicates significant inhibition on migration and invasion of breast cancer cells, angiogenesis
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.